Freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
== Description == Weight loss typically occurs when fewer calories are consumed than is expended by daily activities, physiological processes and physical exercise (known as a caloric deficit). If enough weight is lost due to a reduction in body fat, an individual may move from being overweight (25.0-29.9) or obese (30+) into a healthy weight range (18.5-24.9); however, continued weight loss beyond this point can lead to becoming underweight (< 18.5).
== Probe design == The basic unit of ABPP is the activity-based probe (ABP), which are small-molecule probes engineered to profile enzymatic activities of a range of related enzymes within a complex proteome. Although specific architectures vary, most ABPs share three modular components: (1) a reactive group (RG, sometimes called a "warhead"), (2) a linker or binding element, and (3) a tag used for detection or enrichment. This modularity allows probes to achieve broad yet mechanistically meaningful coverage of an enzyme class while minimizing off-target reactivity.
The collapse of the Soviet Union eventually allowed the US and the newly reconstituted Russian Federation to end their Cold War competition also in space, by agreeing in 1993 on the Shuttle–Mir and International Space Station programs.
=== Cellular co-operation === P. aeruginosa relies on iron as a nutrient source to grow. However, iron is not easily accessible because it is not commonly found in the environment. Iron is usually found in a largely insoluble ferric form. Furthermore, excessively high levels of iron can be toxic to P. aeruginosa. To overcome this and regulate proper intake of iron, P. aeruginosa uses siderophores, which are secreted molecules that bind and transport iron. These iron-siderophore complexes, however, are not specific. The bacterium that produced the siderophores does not necessarily receive the direct benefit of iron intake. Rather, all members of the cellular population are equally likely to access the iron-siderophore complexes. Members of the cellular population that can efficiently produce these siderophores are commonly referred to as cooperators; members that produce little to no siderophores are often referred to as cheaters. Research has shown when cooperators and cheaters are grown together, cooperators have a decrease in fitness, while cheaters have an increase in fitness. The magnitude of change in fitness increases with increasing iron limitation. With an increase in fitness, the cheaters can outcompete the cooperators; this leads to an overall decrease in fitness of the group, due to lack of sufficient siderophore production. These observations suggest that having a mix of cooperators and cheaters can reduce the virulent nature of P. aeruginosa.
Chili mac is a dish prepared using chili con carne and macaroni as primary ingredients, which is often topped or intermingled with cheese. Some versions are made using prepared or homemade macaroni and cheese. It is a common dish in the cuisine of the Midwestern United States, and is also popular in other areas of the United States. Several variations of the dish exist, and prepared canned and boxed versions also exist. It can be a relatively inexpensive dish to prepare, and has been described as a comfort food. Similar dishes include spaghetti red, a chili-topped spaghetti popular around Joplin, Missouri, and Cincinnati chili.
Sources: en.wikipedia.org
The Beighton score can be used to determine generalised joint hypermobility (GJH) related to hypermobility syndrome. The newer term "generalised hypermobility spectrum disorder" includes people with generalised joint hypermobility, often determined using the Beighton score, and other symptoms. Those who do not meet the Beighton score criteria may be diagnosed with historical joint hypermobility spectrum disorder, peripheral hypermobility spectrum disorder, or localised hypermobility spectrum disorder. In comparison to the diagnostic criteria of hypermobile Ehlers–Danlos syndrome, the criteria for hypermobile spectrum disorder are less strict. However, these criteria are differentiated from criteria of other EDS types and therefore its less-strict criteria are only comparable to the criteria of hEDS. As those with HSD experience a considerable amount of discomfort, it is important to focus on the treatment, not the labels. The severity of each condition can be equivalent. In particular, musculoskeletal involvement is a requirement for diagnosis with any form of hypermobility spectrum disorder but not for hypermobile Ehlers–Danlos syndrome. Like hypermobile Ehlers–Danlos syndrome, hypermobility spectrum disorders are associated with orthostatic tachycardia, gastrointestinal disorders, and pelvic and bladder dysfunction.
==== Maintenance phase ==== After the 5–7 day loading phase, muscle creatine stores are fully saturated and supplementation only needs to cover the amount of creatine broken down per day. This maintenance dose was originally reported to be around 2–3 g/day (or 0.03 g/kg/day), however, some studies have suggested 3–5 g/day maintenance dose to maintain saturated muscle creatine.
Extracting helium from air is not economical. For large-scale use, helium is extracted by fractional distillation from natural gas, which can contain as much as 7% helium. Since helium has a lower boiling point than any other element, low temperatures and high pressure are used to liquefy nearly all the other gases (mostly nitrogen and methane). The resulting crude helium gas is purified by successive exposures to lowering temperatures, in which almost all of the remaining nitrogen and other gases are precipitated out of the gaseous mixture. Activated charcoal is used as a final purification step, usually resulting in 99.995% pure Grade-A helium. The principal impurity in Grade-A helium is neon. In a final production step, most of the helium that is produced is liquefied via a cryogenic process. This is necessary for applications requiring liquid helium and also allows helium suppliers to reduce the cost of long-distance transportation, as the largest liquid helium containers have more than five times the capacity of the largest gaseous helium tube trailers. In 2008, approximately 169 million standard cubic meters (SCM) (6.0 × 109 cubic feet) of helium were extracted from natural gas or withdrawn from helium reserves, with approximately 78% from the United States, 10% from Algeria, and most of the remainder from Russia, Poland, and Qatar. By 2013, increases in helium production in Qatar (under the company Qatargas managed by Air Liquide) had increased Qatar's fraction of world helium production to 25%, making it the second largest exporter after the United States.
Cava (stylized in all caps as CAVA) is an American Mediterranean fast casual restaurant chain with locations across the United States. Cava is owned by the publicly traded Cava Group, which purchased Zoës Kitchen in August 2018. The combined company is the largest restaurant operator in the Mediterranean category in the U.S. restaurant industry. Cava also produces a line of Mediterranean cava dips, spreads, and dressings that are sold in grocery stores across the US. As of May 2023, all Zoës Kitchen restaurants have been closed or replaced by Cava restaurants.
==== Triptans (serotonin 5-HT1B and 5-HT1D receptor agonists) ==== Almotriptan (Almogran; Axert; LAS-31416) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [119] Eletriptan (Relert; Relpax; UK-116044) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine, menstrual migraine [120] Frovatriptan (Allegro; Auradol; EN-3266; Frova; Isimig; Migard; Pitunal; Rilamig; SB-209509; SB-209509AX; VML-251) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [121] Naratriptan (Amerge; GR-85548; GR-85548A; Naramig; SMP-948) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [122] Rizatriptan (L-705126; Maxalt; MK-0462; MK-462) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [123] Rizatriptan oral film (INT-0008; RHB-103; Rizafilm; VersaFilm; RizaPort) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [124] Sumatriptan (Imigran Nasal Spray; Imitrex Nasal Spray) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [125] Zolmitriptan (311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomigon) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – cluster headache, menstrual migraine, migraine [126] Zolmitriptan oral dispersible film (zolmitriptan ODF; Zolmitriptan PharmaFilm; Zolmitriptan RapidFilm; Zolmitriptan Renantos Schmelzfilm) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [127]
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.